Bristol Myers Squibb Company $BMY Stock Sold by Axxcess Wealth Management LLC

Key Points

• Axxcess Wealth Management cut its Bristol Myers Squibb stake by 68.5% in the third quarter, selling 43,959 shares and retaining 20,173 shares valued at approximately $1.26 million.
• Other major institutions increased their holdings, including BlackRock and State Street, while institutional investors collectively own 76.41% of BMY’s outstanding shares. An insider also sold 500 shares.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates, and revenue of $12.97 billion, up 5.7% year over year. The company declared a quarterly dividend of $0.63, equivalent to a 4.1% annualized yield, while analysts maintain a “Moderate Buy” consensus rating with a $64.88 target price.

Axxcess Wealth Management LLC decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 68.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,173 shares of the biopharmaceutical company's stock after selling 43,959 shares during the quarter. Axxcess Wealth Management LLC's holdings in Bristol Myers Squibb were worth $1,259,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Lazard Asset Management LLC grew its position in shares of Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock worth $116,693,000 after buying an additional 368,193 shares during the last quarter. Callan Family Office LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $3,575,000. BlackRock Inc. lifted its position in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. Saudi Central Bank lifted its position in Bristol Myers Squibb by 90.2% during the second quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company's stock valued at $8,235,000 after acquiring an additional 67,780 shares during the last quarter. Finally, State Street Corp boosted its stake in Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In related news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.05% of the company's stock.

Bristol Myers Squibb Stock Down 2.3%

NYSE:BMY opened at $61.58 on Friday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The stock's fifty day moving average is $63.26 and its two-hundred day moving average is $60.33. The stock has a market capitalization of $125.79 billion, a price-to-earnings ratio of 9.68, a price-to-earnings-growth ratio of 0.32 and a beta of 0.19. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period in the prior year, the business earned $1.46 EPS. The firm's quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.56 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. Bristol Myers Squibb's payout ratio is currently 55.51%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Sanford C. Bernstein reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 13th. Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. Roth Capital began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating and a $75.00 target price for the company. BMO Capital Markets restated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $82.00 price target (up from $75.00) on shares of Bristol Myers Squibb in a research report on Wednesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $64.88.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers and SystImmune reported that izalontamab brengitecan reduced the risk of disease progression or death by 59% versus chemotherapy in the Phase 3 PANKU-Breast01 trial for advanced HR-positive/HER2-negative breast cancer. The result could strengthen BMY’s oncology pipeline and support a future regulatory filing. Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
• Positive Sentiment: BMY expanded its multi-year collaboration with Tempus AI, licensing multimodal oncology data through 2031 to aid target discovery and drug development. Separately, BMS is collaborating with Pathos AI and Tempus on AI-driven research in Alzheimer’s disease and other neurological conditions, while leading Pathos’s Series E financing and gaining access to its Foundry platform. These deals may improve research productivity and pipeline potential, although financial benefits are longer term. Tempus Expands Strategic Collaboration with Bristol Myers Squibb Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst H. Engel modestly raised Erste Group’s FY2027 EPS forecast to $6.56 from $6.53, matching consensus and suggesting stable expectations for BMY’s earnings power. Bristol Myers Squibb analyst estimate update
• Neutral Sentiment: Phase 1 Breakfree-2 data for the CAR-T therapy zolacabtagene autoleucel in highly active multiple sclerosis provide another pipeline catalyst, but the early-stage study still requires larger and later-stage testing before its commercial value can be assessed. Bristol Myers Squibb Presents Breakfree-2 Results
• Negative Sentiment: Bristol Myers disclosed a patient death in the early-stage cell-therapy study. Even if the event does not ultimately change the program’s development, it introduces a safety overhang and may overshadow the positive efficacy data. Bristol Myers discloses patient death in early-stage cell therapy study
• Negative Sentiment: Pre-earnings coverage anticipates a year-over-year decline in third-quarter earnings, keeping attention on legacy-drug erosion, pipeline execution and BMY’s relatively high debt load. These concerns could outweigh the company’s inexpensive valuation and attractive dividend in the near term. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline

About Bristol Myers Squibb

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.